CAR-T

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

2 Answers available

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

2 Answers available

Is there an optimal bridging radiation dose for aggressive B-cell NHL undergoing CAR T-cell therapy?

What influences your decision to proceed with palliative vs. definitive, and standard vs. hypofractionation dosing regimens?

2 Answers available

Which patients with relapsed/refractory NHL are appropriate for pre-CAR-T bridging radiation therapy?

2 Answers available

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

1 Answer available

How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion?

2 Answers available

How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?

How is this entity distinct from other secondary HLH entities?

2 Answers available

Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers available

How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?

How do you choose between CAR-T and autoSCT, for example?

3 Answers available

How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?

1 Answer available

Is there a role for IL2-receptor antagonists and TNF-alpha inhibitors in cytokine release syndrome as a complication of CAR-T or immunotherapy?

1 Answer available

Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?

2 Answers available

What is the best approach for patients with DLBCL with early relapse (< 6 months) after initially attaining a CR with 6 cycles RCHOP?

Does this differ for a patient who had a longer remission before relapse?

4 Answers available

How do you incorporate CAR-T cell therapy for DLBCL in transplant-eligible patients?

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

4 Answers available

What criteria is needed in relapsed/refractory B-cell ALL to choose CAR-T therapy over conventional stem cell transplant as destination therapy?

1 Answer available

What is your approach to pediatric or AYA patients with B-cell ALL who relapse after CD-19 CAR-T?

1 Answer available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

How do you determine when to give a second CAR-T cell infusion to a pediatric or young adult patient with relapsed/refractory ALL?

2 Answers available

Do you offer fertility preservation to patients prior to CAR-T therapy?

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?